Los Angeles Capital Management
NPCE icon

Los Angeles Capital Management’s Neuropace NPCE Stock Holding History

Los Angeles Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$408K Buy
30,993
+4,178
+16% +$62.7K ﹤0.01% 937
2025
Q4 		$264K Buy
26,815
+425
+2% +$5.68K ﹤0.01% 1138
2025
Q3 		$272K Buy
+26,390
New +$249K ﹤0.01% 1162

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Los Angeles Capital Management's NPCE Position: Q1 2026 in Review

Los Angeles Capital Management increased its Neuropace (NPCE) stake by 16% in Q1 2026, buying an estimated $62.7K and bringing the position to 30,993 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #937.

Los Angeles Capital Management first reported a position in NPCE in Q3 2025 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Los Angeles Capital Management held 30,993 shares of Neuropace worth $408K as of Q1 2026.
  • Los Angeles Capital Management bought 4,178 Neuropace shares in Q1 2026, an estimated $62.7K.
  • Neuropace made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #937 holding.
  • Los Angeles Capital Management first reported a position in Neuropace in Q3 2025 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.